real-time news and commentary for investors
Saturday, Dec 15
2012, 10:30 AM
After a stretch in which it alienated the infinitely patient Warren Buffett, Johnson &...
After a stretch in which it alienated the infinitely patient Warren Buffett, Johnson & Johnson (JNJ) may be poised for strong performance, writes Andrew Bary. While the Oracle was selling, the Street was starting to warm up to the company. Revenue growth is improving, and the dividend - the stock yields 3.45% - should continue to grow at 8% annually for years. Underweight institutional investors might soon find themselves needing to buy.